Teva Pharmaceutical Industries Ltd (TEVA) Issues FY13 Earnings Guidance
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) issued an update on its FY13 earnings guidance on Thursday. The company provided earnings per share guidance of $4.85-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.00, AnalystRatings.NET reports. The company issued revenue guidance of $19.5-20.5 billion, compared to the consensus revenue estimate of $20.09 billion.
A number of analysts have recently weighed in on TEVA shares. Analysts at Zacks reiterated a neutral rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Thursday, September 26th. They now have a $40.00 price target on the stock. On a related note, analysts at Morgan Joseph cut their price target on shares of Teva Pharmaceutical Industries Ltd from $45.00 to $43.00 in a research note to investors on Friday, September 13th. They now have a neutral rating on the stock. Finally, analysts at JPMorgan Chase & Co. downgraded shares of Teva Pharmaceutical Industries Ltd from an overweight rating to a neutral rating in a research note to investors on Friday, September 13th. They now have a $43.00 price target on the stock, down previously from $45.00. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $44.78.
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 39.20 on Thursday. Teva Pharmaceutical Industries Ltd has a 52-week low of $36.63 and a 52-week high of $42.83. The stock has a 50-day moving average of $38.22 and a 200-day moving average of $38.96. The company has a market cap of $33.124 billion and a price-to-earnings ratio of 80.49.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last posted its quarterly earnings results on Thursday, August 1st. The company reported $1.20 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.20. The company had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.94 billion. During the same quarter in the previous year, the company posted $1.28 earnings per share. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Ltd will post $5.00 EPS for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.